Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jul 20;10(15):e34991. doi: 10.1016/j.heliyon.2024.e34991

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig. 6 — Continuous Metformin treatment reversed the expression of TGFβ1, TGFβRⅠ and TRPV1 in situ. (A1) Immunofluorescence assay showed that the number of TGFβ1 positive cells was increased in the affected bone tissues of BCP rats, and it was rarely detected in BCP rats treated with Metformin (Bar = 100 μm). (A2) Immunofluorescence assay displayed that the number of TGFβRI positive cells was increased in L4-6 DRG of BCP rats, and it was rarely detected in BCP rats treated with Metformin (Bar = 100 μm). (A3) Immunofluorescence assay indicated that there was no obvious difference in TGFβRII expression in L4-6 DRG from Sham, BCP and Metformin treatment rats. (A4) The TRPV1 expression was increased in L4-6 DRG of BCP rats, and Metformin treatment clearly reduced TRPV1 expression in situ. (B1–B4) Proportion of TGFβ1, TGFβRI, TGFβRII and TRPV1 positive cells (***P < 0.001 vs Sham and Metformin group, n = 5, one-way ANOVA).